B-amyloid as a Marker for GBM Bioimaging

Trial ID: NCT05820191

Interventional - Phase 2 - Unknown status

This project is aimed at improvement of glioblastoma (GBM) diagnostic strategies for discrimination of tumor progression and chemo- and radiotherapeutic treatment-related changes in brain tissue. The study will elucidate the diagnostic value of PET imaging with use of amyloid-β radioisotope tracer Amyvid (Florbetapir F18) for GBM. The results of the study will provide data for development of new approach for GBM diagnostics.

Conditions

• Glioblastoma

Interventions

• Amyvid, Intravenous Solution

Eligibility

Inclusion criteria

• GBM diagnose confirmed by MRI and histopathology
• Had undergone gross total or subtotal resection of their tumor and developed enlarging and/or new enhancing lesion(s), recommended for second resection
• Had or had not received radiation therapy with concomitant and adjuvant TMZ chemotherapy
• Had pre-operative and follow up conventional MRI, MRS and/or Perfusion MR scans, available for analysis

Exclusion criteria

• Previous allergic reaction to radioisotope tracers

Sponsor

Universidad Central del Caribe, University of Puerto Rico

Source: ClinicalTrials.gov

Search more clinical trials on myTomorrows